HuGE Literature Finder
Records 1 - 4
| A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.
Clinical breast cancer 2015 Sep .
Sawyer Michael B, Pituskin Edith, Damaraju Sambasivarao, Bies Robert R, Vos Larissa J, Prado Carla M M, Kuzma Michelle, Scarfe Andrew G, Clemons Mark, Tonkin Katia, Au Heather-Jane, Koski Sheryl, Joy Anil A, Smylie Michael, King Karen, Carandang Diana, Damaraju Vijaya L, Hanson John, Cass Carol E, Mackey John
| Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Breast cancer research and treatment 2014 Oct 147 (3): 557-70.
Vulsteke C, Pfeil A M, Schwenkglenks M, Pettengell R, Szucs T D, Lambrechts D, Peeters M, van Dam P, Dieudonné A S, Hatse S, Neven P, Paridaens R, Wildiers
| CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Journal of the National Cancer Institute 2012 Mar 104 (6): 452-60.
Rae James M, Drury Suzy, Hayes Daniel F, Stearns Vered, Thibert Jacklyn N, Haynes Ben P, Salter Janine, Sestak Ivana, Cuzick Jack, Dowsett Mitch,
| Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011 Sep 20 (9): 1937-43.
Ahern Thomas P, Christensen Mariann, Cronin-Fenton Deirdre P, Lunetta Kathryn L, Søiland Håvard, Gjerde Jennifer, Garne Jens Peter, Rosenberg Carol L, Silliman Rebecca A, Sørensen Henrik Toft, Lash Timothy L, Hamilton-Dutoit Steph
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: